102 related articles for article (PubMed ID: 8028036)
21. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Matsumoto Y; Takano H; Fojo T
Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
[TBL] [Abstract][Full Text] [Related]
22. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
Gudkov AV; Zelnick CR; Kazarov AR; Thimmapaya R; Suttle DP; Beck WT; Roninson IB
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3231-5. PubMed ID: 8386368
[TBL] [Abstract][Full Text] [Related]
23. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
24. Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine.
Gosland MP; Gillespie MN; Tsuboi CP; Tofiq S; Olson JW; Crooks PA; Aziz SM
Cancer Chemother Pharmacol; 1996; 37(6):593-600. PubMed ID: 8612315
[TBL] [Abstract][Full Text] [Related]
25. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
26. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
Hatanaka H; Abe Y; Naruke M; Asai S; Miyachi H; Kawakami T; Nagata J; Kamochi J; Kijima H; Yamazaki H; Scanlon KJ; Ueyama Y; Nakamura M
Anticancer Res; 2001; 21(2A):879-85. PubMed ID: 11396179
[TBL] [Abstract][Full Text] [Related]
27. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.
Brock I; Hipfner DR; Nielsen BS; Jensen PB; Deeley RG; Cole SP; Sehested M
Cancer Res; 1995 Feb; 55(3):459-62. PubMed ID: 7834606
[TBL] [Abstract][Full Text] [Related]
28. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance.
Kaplan E; Gündüz U
Biomed Pharmacother; 2012 Feb; 66(1):29-35. PubMed ID: 22285073
[TBL] [Abstract][Full Text] [Related]
29. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
30. P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin.
Nielsen D; Eriksen J; Maare C; Jakobsen AH; Skovsgaard T
Br J Cancer; 1998 Nov; 78(9):1175-80. PubMed ID: 9820176
[TBL] [Abstract][Full Text] [Related]
31. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
32. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.
Chaudhary PM; Roninson IB
J Natl Cancer Inst; 1993 Apr; 85(8):632-9. PubMed ID: 8096875
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins.
Koike K; Abe T; Hisano T; Kubo T; Wada M; Kohno K; Kuwano M
Jpn J Cancer Res; 1996 Jul; 87(7):765-72. PubMed ID: 8698628
[TBL] [Abstract][Full Text] [Related]
34. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
35. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.
Slapak CA; Daniel JC; Levy SB
Cancer Res; 1990 Dec; 50(24):7895-901. PubMed ID: 1979251
[TBL] [Abstract][Full Text] [Related]
36. Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.
Ades S; Maxfield LF; Gould CJ; Jones GK; Levy SB
Int J Oncol; 2006 Mar; 28(3):747-53. PubMed ID: 16465381
[TBL] [Abstract][Full Text] [Related]
37. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
38. Characterization of an etoposide-resistant human K562 cell line, K/eto.
Sugawara I; Iwahashi T; Okamoto K; Sugimoto Y; Ekimoto H; Tsuruo T; Ikeuchi T; Mori S
Jpn J Cancer Res; 1991 Sep; 82(9):1035-43. PubMed ID: 1657846
[TBL] [Abstract][Full Text] [Related]
39. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line.
Hua J; Mutch DG; Herzog TJ
Gynecol Oncol; 2005 Jul; 98(1):31-8. PubMed ID: 15921732
[TBL] [Abstract][Full Text] [Related]
40. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene.
Asano T; An T; Mayes J; Zwelling LA; Kleinerman ES
Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):307-13. PubMed ID: 8870683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
